News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx to Host Analyst Day in New York
Management to Review Late Stage Clinical Development and Commercial Potential in Hyperphosphatemia, Pipeline Program in Hyperkalemia and Recent Approval in IBS-C     FREMONT, Calif. , Oct. 10, 2019 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an Analyst Day on
View HTML
Toggle Summary Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference
FREMONT, Calif. , Sept. 17, 2019 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Mike Raab , president and chief executive
View HTML
Toggle Summary Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation
Approval supported by two Phase 3 trials demonstrating a statistically significant reduction in constipation and abdominal pain in adult patients with IBS-C Novel MOA offers a new and differentiated option for patients with IBS-C and the physicians who treat them Discovered and developed by
View HTML
Toggle Summary Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
The primary and all key secondary endpoints were met. Tenapanor in combination with binders met the primary endpoint demonstrating a statistically significant (p=0.0004) reduction of serum phosphorus compared to binders alone. Approximately two times more patients achieved the established serum
View HTML
Toggle Summary Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study
FREMONT, Calif. , Sept. 2, 2019 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that it will hold a conference call tomorrow, September 3 , at
View HTML
Toggle Summary Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights
AMPLIFY clinical trial to read out 3Q19 PHREEDOM clinical trial to read out 4Q19 FREMONT, Calif. , Aug. 9, 2019 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with
View HTML
Toggle Summary Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference
FREMONT, Calif. , May 30, 2019 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today announced that Mike Raab , president and chief executive
View HTML
Toggle Summary Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights
Two Pivotal Phase 3 readouts in 2H 2019 FREMONT, Calif. , May 7, 2019 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business
View HTML
Toggle Summary Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors
FREMONT, Calif. , March 14, 2019 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), today announced the appointment of Geoffrey A. Block , M.D., Vice President, Nephrology at Reata and former Director of Clinical Research in the Denver Nephrology Research Division at Colorado Kidney Care/Denver
View HTML
Toggle Summary Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
- Ardelyx's investigative agent for end-stage renal disease patients on dialysis represents first non-binder innovation to lower patients' phosphate levels, a critically important parameter that is correlated with morbidity and mortality - Ardelyx's approach leverages newly discovered pathway for
View HTML